Pfizer Inc. safe stock for beginners with cancer treatment expansion

Pfizer Inc. (NYSE:PFE) has seen its stock price plummet by over 50% from late 2021 highs, but recent developments suggest a turnaround. On June 8, 2026, the U.S. FDA approved an expanded indication for Pfizer's Hympavzi, and on May 5, the company reported strong Q1 revenues of $14.5 billion, a 2% operational increase year-over-year. Additionally, Pfizer's $43 billion acquisition of Seagen has begun to pay off, with the company now controlling a dominant share of the cancer treatment market.

The market impact of these developments has been positive, with Pfizer's stock being recommended as a safe bet for beginners by several analysts. The company's expansion into the cancer treatment market, driven by the Seagen acquisition, has attracted hedge fund interest, with 25 of the 60 most recent 13F filers holding Pfizer stock. The strong Q1 results and FDA approval have also pushed Pfizer's stock price up, potentially reversing its previous downward trend.

To watch next, investors should keep an eye on Pfizer's upcoming earnings reports, with the next one scheduled for late July 2026. Additionally, the market will be closely watching the progress of Pfizer's pipeline, particularly its cancer treatments, and any regulatory decisions related to these products. Lastly, the company's ability to maintain and grow its market share in the competitive pharmaceutical landscape will be a key factor in determining the narrative's evolution.